Tyrosinemia Society Logo.png
  • Home

  • About

  • News

  • Leading the Way

  • Tyrosinemia Basics

  • Partners

  • Our Supporters

  • Contact Us

  • Get Involved

  • More

    Use tab to navigate through the menu items.
    • facebook
    dna-icon-2316641_640.png

    In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions

    January 3, 2021
    expert-opinion-logo.jpg

    The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism

    July 21, 2020
    louis-reed-pwcKF7L4-no-unsplash.jpg

    New patents for possible tyrosine "harvesting" drug to help eliminate excess tyrosine.

    April 14, 2020
    cycle-baylor.jpg

    Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

    December 18, 2019
    qol_patient_data.png

    Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients

    December 4, 2019
    ensemble_edited.png

    http://ensemblecontrelatyrosinemie.fr/en/

    The Tyrosinemia Society and the French sister society "Ensemble contre la tyrosinemie" partner to share experiences and clinical research directions.

    Orphan disease treatment “at a tipping point” thanks to advances in clinical pharmacology

    Diana LaChance, The University of Alabama in Huntsville
    July 3, 2019

    Tyrosinemia Society, Inc. Partners with PatientsLikeMe to the Tyrosinemia Community

    February 26, 2021
    plm-ts-combined.png

    © 2021 Tyrosinemia Society, Inc.